3 results
Approved WMOCompleted
Primary objective:- To demonstrate that CT-P13 is noninferior to Remicade at Week 6 (Dose 3), in terms of efficacy, asdetermined by the Crohn*s Disease Activity Index (CDAI)-70 response rate.Secondary objectives:-To evaluate long-term secondary…
Approved WMORecruiting
1) Objective: To compare pembrolizumab plus chemotherapy to placebo plus chemotherapy with respect to PFS
Approved WMOCompleted
Primary- To evaluate disease-related characteristics and biomarkers in patients with mycosis fungoides compared to healthy volunteers; Secondary- To evaluate the variability of the selected biomarkers between patients and within patients over time…